Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion.
In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000 mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Based of these results, AA is approved in metastatic CRPC patients in post-docetaxel setting or pre-docetaxel setting in 2013.
Written by:
Boissier E, Loriot Y, Vignot S, Massard C. Are you the author?
Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Institut Gustave-Roussy, Département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Service d'oncologie et hématologie, 4, rue Louis-Pasteur, 28630 Chartres Le Coudray, France.
Reference: Bull Cancer. 2014 Apr;101(4):388-93.
doi: 10.1684/bdc.2014.1932
PubMed Abstract
PMID: 24793632
Article in French.
UroToday.com mCRPC Treatment Section
